American biotech company Novavax announced that it will begin an early-staged trial for a combined influenza/COVID-19 vaccine. The trial will be conducted in Australia and will include 640 adults (between 50 and 70 years of age) and who have either been previously infected with the coronavirus or have received an authorized COVID-19 dose already. The study aims to trial a combination of the Novavax’s COVID-19 vaccine, NVX-CoV2373, and its own Influenza vaccine NanoFlu, together with an adjuvant or vaccine booster. Results are expected at the beginning of 2022.
Read more here.
More on: News Regulatory